Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Adds Potent Drug Capabilities at German Site | Contract Pharma

What are you searching for?

Sign in
Breaking News

Catalent Adds Potent Drug Capabilities at German Site

Catalent Pharma Solutions has expanded its capabilities to include a new potent products area at its Schorndorf site in Germany.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has expanded its capabilities to include a new potent products area at its Schorndorf site in Germany. The company can now provide complex dose form production, overencapsulation and packaging solutions for potent products at its Schorndorf site.

Catalent’s Schorndorf operation provides a range of services to global, regional and local pharmaceutical customers. The Schorndorf facility successfully completed an FDA inspection in the fall of 2009.

“We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our customers, both global and local. I am also pleased that this investment was made here in Schorndorf, as it builds upon our team’s commitment to operational excellence, our regulatory track record, and our consistent focus on meeting our customers’ needs,” said Eric Schmidhaeuser, managing director of the Schorndorf operation.

Click here for more information about Catalent

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters